A timely oral option: single-agent vinorelbine in Desmoid tumors
Gennatas, Spyridon Chamberlain, Florence Smrke, Alannah Stewart, James Hayes, Andrew Roden, Lorna Messiou, Christina Kowa, Jie-Ying Estival, Anna Chauhan, Dharmisha
Gennatas, Spyridon
Chamberlain, Florence
Smrke, Alannah
Stewart, James
Hayes, Andrew
Roden, Lorna
Messiou, Christina
Kowa, Jie-Ying
Estival, Anna
Chauhan, Dharmisha
An error occurred retrieving the object's statistics
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2020-10-02
Subject
Research Projects
Organizational Units
Journal Issue
Abstract
Introduction: Desmoid tumors (DT) are rare collagen-forming tumors that can exhibit locally aggressive patterns of behavior. The aim of this study was to evaluate the efficacy and safety of treatment of DT with single-agent oral vinorelbine.
Materials and methods: A retrospective review of patients treated with vinorelbine 90 mg orally on days 1, 8, and 15 of a 28-day cycle from January 2004 to July 2019 was performed. Response was assessed using RECIST version 1.1. Descriptive statistics were employed.
Results: A total of 29 patients were included. Response rate was 20.7% (6/29), and clinical benefit rate (response by RECIST 1.1 and/or clinical symptom improvement) was 65.5% (19/29). No patient experienced grade 3 or above toxicity. Common toxicities were grade 1-2 nausea (14/26, 48.3%), fatigue (9/26, 31.0%), and diarrhea (4/26, 13.8%).
Conclusion: Single-agent oral vinorelbine is an effective, safe, and well-tolerated treatment for DT. It represents a new oral alternative for management of DT.
Citation
Gennatas S, Chamberlain F, Smrke A, Stewart J, Hayes A, Roden L, Messiou C, Kowa JY, Estival A, Chauhan D, Thway K, Fisher C, van der Graaf WTA, Jones RL, Benson C. A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors. Oncologist. 2020 Dec;25(12):e2013-e2016. doi: 10.1002/ONCO.13516. Epub 2020 Oct 2
Type
Article
Other
Other